Added to YB: 2025-10-03
Pitch date: 2025-10-01
ABCL [bullish]
AbCellera Biologics Inc.
+109.41%
current return
Author Info
No bio for this author
Company Info
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Market Cap
$4.0B
Pitch Price
$6.05
Price Target
N/A
Dividend
N/A
EV/EBITDA
-19.15
P/E
-22.56
EV/Sales
54.17
Sector
Life Sciences Tools and Services
Category
growth
Abcellera: The Palantir of Biotech In the Making.
ABCL: 3 proprietary molecules entering trials Q1 2025+ with vast applications beyond current conditions tested. Superior receptor selectivity (NK3R not NK1R targeting) vs competitors may drive exponential FCF growth if approved. Strong balance sheet, AI-enhanced platform, but binary outcome at 45x P/S.
Read full article (3 min)